Oncology Ventures lead product LiPlaCis is now in phase 2
Hoersholm, Denmark, November 21th, 2016 – Oncology Venture Sweden AB (OV.ST) today announce that the Danish Health Authorities (DKMA) and the Ethics Committee have accepted that the ongoing dose escalation phase 1 + extension phase can continue as a phase 1/2 study. The study title is accordingly: ‘Phase 1/2 study to evaluate the safety and tolerability of LiPlaCis (Liposomal Cisplatin formulation) in patients with advanced or refractory tumours’. The study has until now been running on dedicated Phase 1 Units and can now move to ’normal’ oncology wards. Work is in progress to open 4 sites in